Evidence map›Paper›PMID 39127977›Full record

ArticleInflammopharmacology2024

Preclinical efficacy of oral and nasal rivastigmine-loaded chitosan nano-particles on AlCl

Dina E ElMosbah, Marwa S Khattab, Marwa A Ibrahim, Mona I El-Asssal, Hala M F El Miniawy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dina E ElMosbahDepartment of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt. dinaemadeldeen@cu.edu.eg.ORCID http://orcid.org/0000-0002-6021-0718
Marwa S KhattabDepartment of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt.
Marwa A IbrahimDepartment of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt.
Mona I El-AsssalDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, Cairo, 11835, Egypt.
Hala M F El MiniawyDepartment of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, 12211, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The successful treatment of Alzheimer's disease (AD) is still a big challenge. Rivastigmine is one of the most used drugs for the treatment of AD. The short half-life, lower bioavailability, and less concentration of the drug in the brain after oral delivery are considered the main drawbacks of rivastigmine. To improve these drawbacks, nanostructure-mediated drug delivery has gained more attention. This study investigates the effect of rivastigmine-loaded in optimized chitosan nano-particles (RS-CSNPs) as polymeric nano-carriers by different administration routes (oral and intranasal) on aluminum chloride (AlCl

Indexed as

Administration, IntranasalAluminum ChlorideAlzheimer DiseaseChitosanNanoparticlesRats, WistarRivastigmineAdministration, OralAnimalsBrainDisease Models, AnimalDrug CarriersDrug Delivery SystemsMaleNeuroprotective AgentsOxidative StressAluminum ChlorideChitosanDrug CarriersNeuroprotective AgentsRivastigmineAlzheimer's diseaseCaspase-3HistopathologyNrf-2Rivastigmine nanoparticlesTau

Identifiers

PMID39127977
PMCPMC11550235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.